Shopping Cart 0
Cart Subtotal
USD 0

Duchenne Muscular Dystrophy - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000

Details

Duchenne Muscular Dystrophy-Pipeline Review, H2 2018

 

Summary

 

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy-Pipeline Review, H2 2018, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

 

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.

 

Report Highlights

 

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 18, 8, 43 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 1, 9 and 1 molecules, respectively.

 

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Scope

 

- The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).

- The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)

 

Reasons to buy

 

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Duchenne Muscular Dystrophy-Overview 6

Duchenne Muscular Dystrophy-Therapeutics Development 7

Duchenne Muscular Dystrophy-Therapeutics Assessment 20

Duchenne Muscular Dystrophy-Companies Involved in Therapeutics Development 28

Duchenne Muscular Dystrophy-Drug Profiles 50

Duchenne Muscular Dystrophy-Dormant Projects 252

Duchenne Muscular Dystrophy-Discontinued Products 256

Duchenne Muscular Dystrophy-Product Development Milestones 257

Appendix 268


List Of Figure

List of Figures

Number of Products under Development for Duchenne Muscular Dystrophy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Duchenne Muscular Dystrophy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Akashi Therapeutics Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Antisense Therapeutics Ltd, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Avidity Biosciences LLC, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Beech Tree Labs Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Biogen Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Bioleaders Corp, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Biophytis SA, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Capricor Therapeutics Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Catabasis Pharmaceuticals Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by CRISPR Therapeutics, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Cumberland Pharmaceuticals Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Editas Medicine Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Eloxx Pharmaceuticals Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Fate Therapeutics Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by FibroGen Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Fulcrum Therapeutics Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Galapagos NV, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Genethon SA, H2 2018

Duchenne Muscular Dystrophy-Pipeline by GTx Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by GW Pharmaceuticals Plc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Italfarmaco SpA, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Milo Biotechnology LLC, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Mitobridge Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Mitochon Pharmaceuticals Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by N-Gene Research Laboratories Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by NicOx SA, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Nobelpharma Co Ltd, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Novartis AG, H2 2018

Duchenne Muscular Dystrophy-Pipeline by NS Pharma Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by PeptiDream Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Pfizer Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Progenitor Therapeutics Ltd, H2 2018

Duchenne Muscular Dystrophy-Pipeline by PTC Therapeutics Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by ReveraGen BioPharma Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Santhera Pharmaceuticals Holding AG, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Sarepta Therapeutics Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Solid Biosciences Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by SOM Biotech SL, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Strykagen Corp, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Summit Therapeutics Plc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Taiho Pharmaceutical Co Ltd, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Teijin Pharma Ltd, H2 2018

Duchenne Muscular Dystrophy-Pipeline by WAVE Life Sciences Ltd, H2 2018

Duchenne Muscular Dystrophy-Dormant Projects, H2 2018

Duchenne Muscular Dystrophy-Dormant Projects, H2 2018 (Contd..1), H2 2018

Duchenne Muscular Dystrophy-Dormant Projects, H2 2018 (Contd..2), H2 2018

Duchenne Muscular Dystrophy-Dormant Projects, H2 2018 (Contd..3), H2 2018

Duchenne Muscular Dystrophy-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Duchenne Muscular Dystrophy Therapeutic Products under Development, Key Players in Duchenne Muscular Dystrophy Therapeutics, Duchenne Muscular Dystrophy Pipeline Overview, Duchenne Muscular Dystrophy Pipeline, Duchenne Muscular Dystrophy Pipeline Assessment


Companies

Akashi Therapeutics Inc

Antisense Therapeutics Ltd

Avidity Biosciences LLC

Beech Tree Labs Inc

Biogen Inc

Bioleaders Corp

Biophytis SA

Capricor Therapeutics Inc

Catabasis Pharmaceuticals Inc

CRISPR Therapeutics

Cumberland Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Editas Medicine Inc

Eloxx Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

FibroGen Inc

Fulcrum Therapeutics Inc

Galapagos NV

Genethon SA

GTx Inc

GW Pharmaceuticals Plc

Italfarmaco SpA

Milo Biotechnology LLC

Mitobridge Inc

Mitochon Pharmaceuticals Inc

N-Gene Research Laboratories Inc

NicOx SA

Nobelpharma Co Ltd

Novartis AG

NS Pharma Inc

PeptiDream Inc

Pfizer Inc

Progenitor Therapeutics Ltd

PTC Therapeutics Inc

ReveraGen BioPharma Inc

Santhera Pharmaceuticals Holding AG

Sarepta Therapeutics Inc

Solid Biosciences Inc

SOM Biotech SL

Strykagen Corp

Summit Therapeutics Plc

Taiho Pharmaceutical Co Ltd

Teijin Pharma Ltd

WAVE Life Sciences Ltd

Company Profile

Company Profile Title

Duchenne Muscular Dystrophy-Pipeline Review, H2 2018

 

Summary

 

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy-Pipeline Review, H2 2018, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

 

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.

 

Report Highlights

 

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 18, 8, 43 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 1, 9 and 1 molecules, respectively.

 

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Scope

 

- The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).

- The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)

 

Reasons to buy

 

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 5

Duchenne Muscular Dystrophy-Overview 6

Duchenne Muscular Dystrophy-Therapeutics Development 7

Duchenne Muscular Dystrophy-Therapeutics Assessment 20

Duchenne Muscular Dystrophy-Companies Involved in Therapeutics Development 28

Duchenne Muscular Dystrophy-Drug Profiles 50

Duchenne Muscular Dystrophy-Dormant Projects 252

Duchenne Muscular Dystrophy-Discontinued Products 256

Duchenne Muscular Dystrophy-Product Development Milestones 257

Appendix 268


List Of Figure

List of Figures

Number of Products under Development for Duchenne Muscular Dystrophy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Duchenne Muscular Dystrophy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Akashi Therapeutics Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Antisense Therapeutics Ltd, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Avidity Biosciences LLC, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Beech Tree Labs Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Biogen Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Bioleaders Corp, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Biophytis SA, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Capricor Therapeutics Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Catabasis Pharmaceuticals Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by CRISPR Therapeutics, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Cumberland Pharmaceuticals Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Editas Medicine Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Eloxx Pharmaceuticals Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Fate Therapeutics Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by FibroGen Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Fulcrum Therapeutics Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Galapagos NV, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Genethon SA, H2 2018

Duchenne Muscular Dystrophy-Pipeline by GTx Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by GW Pharmaceuticals Plc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Italfarmaco SpA, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Milo Biotechnology LLC, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Mitobridge Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Mitochon Pharmaceuticals Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by N-Gene Research Laboratories Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by NicOx SA, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Nobelpharma Co Ltd, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Novartis AG, H2 2018

Duchenne Muscular Dystrophy-Pipeline by NS Pharma Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by PeptiDream Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Pfizer Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Progenitor Therapeutics Ltd, H2 2018

Duchenne Muscular Dystrophy-Pipeline by PTC Therapeutics Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by ReveraGen BioPharma Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Santhera Pharmaceuticals Holding AG, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Sarepta Therapeutics Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Solid Biosciences Inc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by SOM Biotech SL, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Strykagen Corp, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Summit Therapeutics Plc, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Taiho Pharmaceutical Co Ltd, H2 2018

Duchenne Muscular Dystrophy-Pipeline by Teijin Pharma Ltd, H2 2018

Duchenne Muscular Dystrophy-Pipeline by WAVE Life Sciences Ltd, H2 2018

Duchenne Muscular Dystrophy-Dormant Projects, H2 2018

Duchenne Muscular Dystrophy-Dormant Projects, H2 2018 (Contd..1), H2 2018

Duchenne Muscular Dystrophy-Dormant Projects, H2 2018 (Contd..2), H2 2018

Duchenne Muscular Dystrophy-Dormant Projects, H2 2018 (Contd..3), H2 2018

Duchenne Muscular Dystrophy-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Duchenne Muscular Dystrophy Therapeutic Products under Development, Key Players in Duchenne Muscular Dystrophy Therapeutics, Duchenne Muscular Dystrophy Pipeline Overview, Duchenne Muscular Dystrophy Pipeline, Duchenne Muscular Dystrophy Pipeline Assessment


Companies

Akashi Therapeutics Inc

Antisense Therapeutics Ltd

Avidity Biosciences LLC

Beech Tree Labs Inc

Biogen Inc

Bioleaders Corp

Biophytis SA

Capricor Therapeutics Inc

Catabasis Pharmaceuticals Inc

CRISPR Therapeutics

Cumberland Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Editas Medicine Inc

Eloxx Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

FibroGen Inc

Fulcrum Therapeutics Inc

Galapagos NV

Genethon SA

GTx Inc

GW Pharmaceuticals Plc

Italfarmaco SpA

Milo Biotechnology LLC

Mitobridge Inc

Mitochon Pharmaceuticals Inc

N-Gene Research Laboratories Inc

NicOx SA

Nobelpharma Co Ltd

Novartis AG

NS Pharma Inc

PeptiDream Inc

Pfizer Inc

Progenitor Therapeutics Ltd

PTC Therapeutics Inc

ReveraGen BioPharma Inc

Santhera Pharmaceuticals Holding AG

Sarepta Therapeutics Inc

Solid Biosciences Inc

SOM Biotech SL

Strykagen Corp

Summit Therapeutics Plc

Taiho Pharmaceutical Co Ltd

Teijin Pharma Ltd

WAVE Life Sciences Ltd